TOP > 外国特許検索 > METHOD FOR PRODUCING MESENCHYMAL STEM CELLS, THERAPEUTIC EFFECT MARKER OF MESENCHYMAL STEM CELLS, METHOD FOR DETERMINING THERAPEUTIC EFFECTS OF MESENCHYMAL STEM CELLS, AND CELLULAR PREPARATION CONTAINING MESENCHYMAL STEM CELLS

METHOD FOR PRODUCING MESENCHYMAL STEM CELLS, THERAPEUTIC EFFECT MARKER OF MESENCHYMAL STEM CELLS, METHOD FOR DETERMINING THERAPEUTIC EFFECTS OF MESENCHYMAL STEM CELLS, AND CELLULAR PREPARATION CONTAINING MESENCHYMAL STEM CELLS 新技術説明会

外国特許コード F180009486
整理番号 16008-WO01
掲載日 2018年10月12日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP016883
国際公開番号 WO 2018199194
国際出願日 平成30年4月25日(2018.4.25)
国際公開日 平成30年11月1日(2018.11.1)
優先権データ
  • 特願2017-086514 (2017.4.25) JP
  • 特願2017-092030 (2017.5.3) JP
発明の名称 (英語) METHOD FOR PRODUCING MESENCHYMAL STEM CELLS, THERAPEUTIC EFFECT MARKER OF MESENCHYMAL STEM CELLS, METHOD FOR DETERMINING THERAPEUTIC EFFECTS OF MESENCHYMAL STEM CELLS, AND CELLULAR PREPARATION CONTAINING MESENCHYMAL STEM CELLS 新技術説明会
発明の概要(英語) [Problem] To provide a cellular preparation containing highly therapeutically effective mesenchymal stem cells (MSCs).
[Solution] The present invention provides a method for producing activated MSCs, the method comprising a step for using a cell culture carrier having a three-dimensional structure consisting of fibers to culture MSCs in a medium containing an activating agent derived from a mammalian fetal appendage. Also, provided are: a therapeutic effect marker of MSCs, wherein the marker is selected from the group consisting of p16ink4a, p14ARF, CDK4, CDK6, RB, and CD47; a method for determining therapeutic effects using said marker; a method for determining the adaptability of MSCs with respect to a treatment for enhancing therapeutic effects; a cell preparation containing MSCs; and a method for producing the cell preparation.
従来技術、競合技術の概要(英語) BACKGROUND ART
Mesenchymal stem cells (Mesenchymal stem cell, hereinafter also referred to as MSC) is, perhaps the ability to self-replicating and have the ability to a stem cell, osteoblast, chondrocyte cells, fat cells, muscle cells to differentiate into cells such as mesenchymal belonging to the well, such as hepatocytes or cells also have the ability to differentiate than definitive.In the MSC, itself produced by the liquid agent and cell adhesion interactions paracrine effect have been known.MSC is, based on these actions, the repair of the target tissue or cell, a regenerative capacity, and exhibits an anti-inflammatory such as ability to control, as a result, a variety of diseases are considered to represent the therapeutic effect.
The MSC, can be easily isolated and cultured up the force in the growth, the number of cells in a short time can be secured to the implantable, immune rejection is not a self-implantation, are less ethical issues, it is not necessary to pre-treatment by low immunogenicity allograft practical reasons, as the material of the ideal cell transplantation therapy, a treatment for various diseases has been applied to study.
The inventors of the present invention, the MSC is used to establish cell transplantation therapy in the course of, for example a diabetic patient in the patient's abnormal MSC in the MSC, specifically as described above or a variety of capability of the capability of the MSC and compared with that of a normal as a result, the effect of disease or therapeutic effect is lost as compared with the normal MSC MSC is reduced, and mammals extract from the associated MSC and activating the abnormal treatment efficacy can be restored, and such activation treatment using autografts the MSC can be found or the like, attached to mammals as an active ingredient extract from abnormal activation agent for the MSC to the invention, and filed a patent application (Patent Document 1).The activation agent is, in particular, the treatment step becomes necessary for the patient at the point of the MSC can be autografts, has important significance.
Patent Document 1 to the MSC of the activation agent is abnormal, the appendage and mammals, for example human umbilical cord tissue or as an extract from the placental tissue can be manufactured.Fortunately, including humans and mammals appendages, relatively easily available can be also expected constant supply quantity is in a biological sample.However, the application of the MSC of the cell transplantation therapy the patient is desirable, for example steadily increasing in proportion to an increase in the world a number of diabetic patients of the MSC to allow for a self-implantation, and mammals are extracted from the appendage and the supply amount of the activation agent, and will not be sufficient.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAPPORO MEDICAL UNIVERSITY
  • 発明者(英語)
  • CHIKENJI Takako
  • FUJIMIYA Mineko
  • SAITO Yuki
  • NAKANO Masako
  • OTANI Miho
  • MIZUE Yuka
  • MATSUMURA Takashi
  • KAMIYA Kozue
国際特許分類(IPC)
参考情報 (研究プロジェクト等) 国立研究開発法人日本医療開発機構橋渡し研究戦略的推進プログラム

PAGE TOP

close
close
close
close
close
close